Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers

Le Zhang†, Cuixia Li† and Xiulan Su*

Abstract
An increasing number of studies have shown that long noncoding RNAs (lncRNAs) play important roles in diverse cellular processes, including proliferation, apoptosis, migration, invasion, chromatin remodeling, metabolism and immune escape. Clinically, the expression of MIR22HG is increased in many human tumors (colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, and thyroid carcinoma), while in others (esophageal adenocarcinoma and glioblastoma), it is significantly decreased. Moreover, MIR22HG has been reported to function as a competitive endogenous RNA (ceRNA), be involved in signaling pathways, interact with proteins and interplay with miRNAs as a host gene to participate in tumorigenesis and tumor progression. In this review, we describe the biological functions of MIR22HG, reveal its underlying mechanisms for cancer regulation, and highlight the potential role of MIR22HG as a novel cancer prognostic biomarker and therapeutic target that can increase the efficacy of immunotherapy and targeted therapy for cancer treatment.

Keywords: Long noncoding RNAs, MIR22HG, Tumorigenesis, Therapeutic target

Background
With the development of genome-wide sequencing technology, there is a deeper understanding of the transcriptomes of organisms. It is currently believed that > 90% of noncoding RNAs (ncRNAs) in the human genome play important biological roles, whereas they were previously considered “transcriptional noise” or “transcriptional waste” [1, 2]. Depending on their length, ncRNAs can be divided into two classes, small noncoding RNAs (ncRNA < 200 nt), including miRNAs, siRNAs, and piRNAs, and long noncoding RNAs (lncRNAs > 200 nt), both of which lack the ability to encode proteins [3]. An increasing number of studies have shown that lncRNAs play important roles in regulating important cell biological functions, such as cell proliferation, apoptosis, migration, invasion, drug resistance and the immune response [4, 5]. In addition, the abnormal expression of lncRNAs, such as MALAT1, HOTAIR, H19 and TUG1, is closely related to the occurrence and development of various malignant tumors [6, 7]. This article summarizes the related research reports on MIR22HG in common tumors, summarizes its biological functions and potential mechanisms in tumors, and provides clues for its application in diagnosis, efficacy and prognosis.

LncRNAs are regulatory RNAs with a length greater than 200 nt and lack protein-coding potential. Increasing evidence has shown that lncRNAs regulate the molecular processes of tumors at the transcriptional, translational, and epigenetic levels. If located in the cytoplasm, lncRNAs may play a regulatory role in “stabilizing RNAs”, “regulating mRNA translation”, acting as “ceRNAs”, “acting as miRNA precursors” or “mediating protein modifications” [8]; if located in the nucleus, lncRNAs play a regulatory role in two ways: “cis-acting” or “trans-acting” [9, 10].
Furthermore, certain lncRNAs show cell- and tissue-specific expression patterns that are critical for their functional analysis and exploration of the potential of lncRNAs as diagnostic, prognostic, and therapeutic targets in cancer [11–18]. Many lncRNAs and their functions or mechanisms need to be further studied, some of which have currently highly attracted the attention of researchers.

In this review, we note that lncRNA NR 028502.1 is located in 17p13.3, a chromosomal region that is frequently deleted or hypermethylated or shows loss of heterozygosity [19, 20]. NR 028502.1 was identified as a lncRNA in the Encyclopedia of DNA Elements (ENCODE) project and is currently annotated as being dysregulated with respect to various human cancers. It has four different transcripts: MIR22HG-1 (2659 bp, transcript variant 1), MIR22HG-2 (1852 bp, transcript variant 2), MIR22HG-3 (1439 bp, transcript variant 3), and MIR22HG-4 (1356 bp, transcript variant 4). Existing studies have shown that MIR22HG functions as a tumor suppressor in many cancers, such as gastric cancer, colorectal cancer, esophageal cancer, lung cancer and hepatocellular carcinoma. However, in esophageal adenocarcinoma and glioblastoma, MIR22HG acts as a tumor promoter to facilitate tumor progression. Considering the differential expression and significant biological function of MIR22HG, it may have great value for diagnostic, prognostic, and therapeutic cancer research. Therefore, in-depth research on the roles of MIR22HG in different tumors and its possible mechanisms of action will provide new insight into clinical cancer treatment. This article provides an overview of existing research on MIR22HG and highlights its promising clinical application as a potential biomarker for the prevention, diagnosis and treatment of cancer.

**Regulatory mechanisms of MIR22HG in cancer**

Studies so far suggest that lncRNAs play critical roles in both normal cellular functions and diseases, including cancer. MIR22HG, a well-studied lncRNA, has been shown to function as a master regulator in diverse malignancies and thus can play a critical role in various aspects of carcinogenesis, including proliferation, apoptosis, invasion, and metastasis (Table 1). Importantly, the aberrant expression of MIR22HG is significantly associated with important clinical characteristics, such as advanced tumor size, stage, TNM stage and overall survival in various kinds of human cancer (Table 2). Various mechanisms have been implicated in the MIR22HG-mediated regulation of cancer progression; for example, MIR22HG has been reported to function as a competitive endogenous RNA (ceRNA) (Fig. 1a), be involved in signaling pathways (Fig. 1b), interact with proteins (Fig. 1c) and interplay with miRNAs as a host gene (Fig. 1d).

**Function as a ceRNA**

One of the most well-characterized mechanisms of lncRNAs is functioning as a ceRNA or “sponge” for miRNAs. ceRNAs are involved in posttranscriptional regulation, as they compete with miRNAs through the same miRNA sequence during RNA transcription to regulate the expression of downstream target genes [32–35].

### Table 1 Functional characterization of MIR22HG in various tumors

| Tumor type               | Expression | Role        | Functional role                                      | Related genes and pathways                                      | References |
|--------------------------|------------|-------------|-----------------------------------------------------|------------------------------------------------------------------|------------|
| thyroid carcinoma        | down       | tumor       | cell proliferation, migration, invasion and apoptosis | Hippo signaling pathway, miR-24-3p and p27kip1                     | [21, 22]   |
| hepatocellular carcinoma | down       | tumor       | cell proliferation, migration, and invasion         | miR-22-3p, HMGB1, HuR, miR-10a-5p, NCOR2, β-catenin and EMT          | [23, 24]   |
| endometrial carcinoma    | down       | tumor       | cell proliferation, apoptosis and the cell cycle    | miR-141-3p and DAPK1                                             | [25]       |
| cholangiocarcinoma       | down       | tumor       | cell proliferation, migration, and invasion         | Wnt/β-catenin signaling pathway, β-catenin, cyclin D1 and c-myc   | [26]       |
| colorectal cancer        | down       | tumor       | cell proliferation and migration                    | SMAD2, SMAD4, TGFβ signaling pathway, EMT, and CD8A              | [27]       |
| gastric cancer           | down       | tumor       | cell proliferation, migration, and invasion         | Notch2 signaling pathway and HEY1                                 | [28]       |
| esophageal adenocarcinoma| up         | tumor       | cell proliferation, migration, invasion and apoptosis| STAT3, c-Myc and p-FAK                                           | [29]       |
| non-small cell lung cancer| down     | tumor       | cell proliferation, migration, and invasion         | Ybx1, MET, and p21                                               | [30]       |
| glioblastoma             | up         | tumor       | cell proliferation and invasion                     | MIR-22-3p/miR-22-5p, SFRP2/PCDH15, ACIL6JTK and Wnt/β-catenin signaling pathway | [31]       |
Mounting evidence has demonstrated that ceRNAs play a vital role in cancer progression [35–37].

More recently, MIR22HG has also emerged as exhibiting ceRNA functions in many cancer types, such as thyroid carcinoma (TC), endometrial carcinoma (EC) and hepatocellular carcinoma (HCC) (Fig. 2). Chen et al. revealed that MIR22HG was downregulated in TC tumor tissues compared with nontumor tissues using 40 pairs of papillary thyroid carcinoma tissues through qRT-PCR detection. Further biological function studies have demonstrated that MIR22HG suppresses the growth, migration and invasion of TC cells. Systematically, MIR22HG acts as a ceRNA to upregulate p27kip1 by directly binding with miR-24-3p, which inhibits the malignant phenotype of TC cells [21] (Fig. 2a). Moreover, the authors reported that low MIR22HG expression was related to tumor size \( (P = 0.015) \), TNM stage \( (P = 0.022) \) and poor overall survival \( (P = 0.030) \) by qRT-PCR detection. Another study by Qin et al. verified these findings. They reported that the downregulation of MIR22HG was significantly related to the lymph node metastasis status \( (P < 0.01) \), the residual tumor status \( (P < 0.05) \), N stage \( (P < 0.05) \), tumor grade \( (P < 0.001) \) and T stage \( (P < 0.001) \) while high MIR22HG expression was significantly correlated with the disease recurrence rate \( (P < 0.01) \), overall survival time \( (P = 0.0665) \) and disease-free survival time \( (P < 0.05) \) in TC by analyzing TCGA, GSE29265, GSE33630, and GSE55091 public datasets.

Wu et al. found that MIR22HG was significantly decreased in 120 HCC tissues compared with adjacent nontumor liver tissues by employing qRT-PCR. Furthermore, low MIR22HG expression was associated with short overall survival \( (P = 0.045) \) and poor disease-free survival \( (P = 0.036) \). Patients with high MIR22HG expression exhibited better overall survival (145-patient cohort: \( P = 0.001 \); TCGA cohort: \( P = 0.015 \)) and disease-free survival (145-patient cohort: \( P = 0.042 \); TCGA cohort: \( P = 0.003 \)) than those with low MIR22HG expression.

Cholangiocarcinoma Low MIR22HG expression was positively correlated with advanced clinical stage (TNM) \( (P = 0.039) \), large tumor size \( (P = 0.002) \), lymph node metastasis \( (P = 0.0001) \), and poor overall survival \( (P = 0.0009) \).

colorectal cancer Low MIR22HG expression was significantly associated with poor overall survival \( (P = 0.0008) \) and disease-free survival \( (P = 0.0009) \).

gastric cancer Low MIR22HG expression indicated a low 5-year overall survival rate \( (P < 0.05) \).

non-small cell lung cancer Low MIR22HG expression was correlated with poor patient survival \( (P = 0.003) \) in an independent UM cohort including 101 LUAD tissues and 27 normal lung tissues.
gastrointestinal stromal tumor (GIST) High MIR22HG expression was associated with patient age \( (P < 0.001) \), Karnofsky Performance Status score \( (P < 0.001) \), advanced tumor grade and poor overall survival \( (P < 0.05) \).
Involvement in signaling pathways

Signaling pathways coordinate communication to enable cells to respond to intracellular or extracellular stimuli. There are many different signaling pathways that contribute to development and cellular homeostasis [42–44]. In diseases, especially cancer, aberrant signaling has been identified as a key mechanism of cancer progression and metastasis [45]. Growing evidence suggests that the MIR22HG-mediated dysregulation of signaling pathways is central to many different types of cancer (Fig. 3).

Wnt/β-catenin signaling pathway

Wnt/β-catenin signaling is an evolutionarily conserved regulatory pathway that has diverse roles in governing cell fate, proliferation, migration, polarity, and death [46, 47]. Accumulating evidence has shown that inappropriate activation of the Wnt/β-catenin pathway is an important mechanism for cancer progression [48–51], and therapeutics targeting Wnt/β-catenin signaling have shown promising clinical applications [52–54].

A report by Hu et al. showed that MIR22HG was downregulated in cholangiocarcinoma (CCA) issues and cell lines by RT-qPCR. The low expression of MIR22HG in CCA tissues was positively correlated with an advanced clinical stage (TNM) (P = 0.039), large tumor size (P = 0.002), lymph node metastasis (P = 0.0001), and poor overall survival (P = 0.020) [26]. The Wnt/β-catenin signaling pathway is involved in the regulation of downstream c-myc, cyclin D1 and other oncogenes that play an important role in tumor cell proliferation and apoptosis [55, 56]. Importantly, the proto-oncogene c-myc is a vital cell cycle regulator in DNA synthesis and cell cycle progression [57, 58]. Hu et al. reported that MIR22HG negatively regulated the Wnt/β-catenin signaling pathway by downregulating the expression of β-catenin, cyclin D1 and c-myc, leading to the inhibition of cell proliferation, migration and invasion in CCA cells. Further in vivo studies in which mouse subcutaneous xenografts were used confirmed that MIR22HG suppresses CCA tumorigenesis (Fig. 3a). In conclusion, MIR22HG may be a novel target for diagnosis and therapy in CCA [26].
Epithelial-mesenchymal transition (EMT) signaling pathway

EMT is a biological process in which epithelial cells lose their characteristic apical-basal polarity and markers while acquiring the characteristics of mesenchymal cells, with high migration and invasion abilities [59]. In recent years, EMT has become a hot spot of cancer research because of its roles in the initial process of tissue carcinogenesis. EMT markers are closely associated with the EMT process and EMT-related migration, invasion, proliferation, antiapoptosis, stemness, and tumor radio/chemosensitivity of cancer cells [60, 61].

Xu et al. reported that MIR22HG was downregulated in colorectal cancer (CRC) tissues and cells compared with normal tissues and cells, as determined by qRT-PCR [27]. Functional analyses revealed that MIR22HG inhibits CRC cell proliferation, migration and invasion in vitro. Then, the authors employed mouse subcutaneous xenograft models and three metastasis models, namely, an intestine metastasis mouse model, a lung metastasis mouse model and an orthotopic hepatic metastasis mouse model, to examine the effect of MIR22HG on tumor growth and metastasis in vivo. The results indicated that tumors formed by MIR22HG-overexpressing cells were smaller and weighed less than tumors formed by control cells and exhibited fewer metastatic nodules and sparse and small metastatic foci. Moreover, they discovered that MIR22HG overexpression inhibited the EMT process, and MIR22HG silencing produced the opposite effect. Silencing MIR22HG decreased the expression of epithelial markers (E-cadherin, ZO-1 and Occludin) and increased the expression of mesenchymal markers (N-cadherin, vimentin and fibronectin). Systematically, MIR22HG inhibits the interaction between SMAD2 and SMAD4 of the TGFβ pathway. Blocking the formation of the SMAD complex also prevents its binding to the promoter of SNAI1 and further suppresses the EMT process (Fig. 3b). These results imply that the MIR22HG-mediated SMAD2/4-SNAI1 axis plays a critical role in CRC progression by regulating EMT signaling pathways. Importantly, an increasing body of evidence has shown that the TGFβ pathway can reshape the immune environment of tumors [62, 63]. The authors further investigated the function of MIR22HG in immune using syngeneic immunocompetent mouse model C57BL/6 [27]. The combination of MIR22HG and aPD-L1 enhanced sensitivity to immunotherapy, suppressed tumor growth, and prolonged the overall survival of mice by promoting CD8 T cell infiltration and facilitating immunotherapy in CRC. These observations indicate the potential application of
MIR22HG in CRC immunotherapy by acting as a tumor suppressor.

**Notch signaling pathway**
The Notch family is a highly conserved and important transmembrane signaling protein family involved in cell development, differentiation, proliferation and apoptosis [64]. The role of Notch signaling in cancer is highly context-dependent [65]. It can act as an oncogene in T cell acute lymphoblastic leukemia (T-ALL), breast cancer, and ovarian cancer, while it can also exert an important tumour-suppressor function in other cancers, such as HCC, forebrain glioma, and head and neck squamous cell carcinoma (HNSCC) [66, 67]. Given its complicated role in tumorigenesis, the Notch signaling pathway will need to be explored in more detail.

Li et al. reported that MIR22HG was downregulated in 43 pairs of human gastric cancer (GC) tissues compared to 21 pairs of matched normal tissues by RT-qPCR [28]. Clinicopathological analysis showed that low MIR22HG expression correlated with poor 5-year overall survival (P < 0.05) in GC patients. The authors found that upregulated MIR22HG may suppress GC cell proliferation, invasion and migration in vitro. In addition, a mechanistic investigation revealed that MIR22HG negatively regulates NOTCH2 signaling by downregulating the expression of HEY1 and nuclear NOTCH2 [28]. MIR22HG knockdown did not influence the expression of NOTCH2 but markedly enhanced that of nuclear NOTCH2. These data suggest that MIR22HG inhibits GC progression by attenuating NOTCH2 signaling (Fig. 3c).

**STAT3 signaling pathway**
The STAT3 signaling pathway has been demonstrated to be important for cancer progression. First, it transduces signals from numerous receptor and nonreceptor tyrosine kinases that are frequently activated in cancer cells [68]. Second, as a transcription factor, STAT3 regulates the expression of many oncogenes, such as c-cyclin B1, CDC2, p53, MCL-1, survivin, VEGF, BCL2 and BAX [69]. Third, growing evidence suggests that STAT3 signaling plays a crucial role in the suppression of tumor immune surveillance and may be a candidate therapeutic target for multiple antitumor immune responses [70]. In addition, cumulative research has shown that the STAT3 signaling pathway is activated in a variety of tumors, such as breast cancer [71], melanoma [72], brain tumors...
translation, and signaling, thus participating in the posttranscriptional gene regulation, such as splicing, LncRNA-protein interactions exert essential functions in divergent functions. Upregulated p21 is associated with poor survival in patients with glioma and prostate, cervical, ovarian, and esophageal cancers. However, the opposite is observed in other tumors, such as breast, gastric, and ovarian cancers [30]. In this study, the authors revealed the biological role of p21 as a potent oncogene that promotes tumor growth in NSCLC and shed light on a new therapeutic strategy for the regulatory mechanism of p21 mediated by IncRNA-protein interactions [30].

Zhang’s team measured MIR22HG levels in a 52-patient cohort by qRT-PCR (P < 0.001), analyzed TCGA and the GSE14520 cohorts (P < 0.001 for both cohorts) and revealed that MIR22HG was comparatively expressed at low levels in HCC tissues. Kaplan-Meier analysis of overall survival and disease-free survival (log-rank) in the 145-patient cohort and the TCGA cohort revealed that patients with high MIR22HG expression exhibited better overall survival (145-patient cohort: P = 0.001; TCGA cohort: P = 0.015) and disease-free survival (145-patient cohort: P = 0.042; TCGA cohort: P = 0.003) than those with low MIR22HG expression. Functionally, biological studies have revealed that the overexpression of MIR22HG dramatically inhibits cell proliferation, migration and invasion in vitro. Moreover, the overexpression of MIR22HG significantly inhibits tumor growth and metastasis in vivo according to mouse subcutaneous xenograft models and a lung metastasis mouse model. Conversely, the silencing of MIR22HG promotes cell proliferation both in vitro and in vivo. Mechanistically, MIR22HG can interact with the human antigen R (HuR) protein, an RNA-binding protein positively associated with malignant aggressiveness [83–85]. This IncRNA-protein interaction increases MIR22HG stability and regulates the subcellular localization of HuR, resulting in the decreased expression of HuR-stabilized oncoproteins such as β-catenin, CCNB1 (encoding cyclin B1), HIF1A (encoding hypoxia-inducible factor-1α), BCL2 (encoding apoptosis regulator Bcl2), COX2 (encoding cyclooxygenase COX2), and C-FOS (encoding the nuclear phosphoprotein c-Fos) and thereby inhibiting the proliferation, invasion and migration of HCC (Fig. 4b). Importantly, their investigation may help identify potential biomarkers that can improve the diagnosis and treatment of HCC [24].

Interplay with miRNAs as a host gene
The regulatory relationship between miRNAs and their host genes provides another mechanism for IncRNA-mediated gene expression. A previous study described MIR22HG as a host gene of miR-22 [86]. Two independent studies examined whether MIR22HG functions as the host gene of miR-22 in cancer progression (Fig. 5).
Han et al. revealed that the expression of MIR22HG was higher in glioblastoma (GBM) and glioma stem-like cells than in normal neural stem cells and that increased MIR22HG was correlated with poor overall survival ($P < 0.0001$) in an analysis of a TCGA dataset. Silencing MIR22HG inhibited GBM cell proliferation and invasion in vitro. In vivo studies in which mouse subcutaneous xenograft and brain orthotopic xenograft models were used have revealed that MIR22HG inhibits tumor growth and metastasis. A mechanistic analysis revealed that MIR22HG, as a host gene of miR-22, is strongly associated with the expression of miR-22-3p and miR-22-5p. Rescue experiments showed that the overexpression of miR-22 is sufficient to restore the MIR22HG depletion-induced inhibition of GBM cell proliferation and invasion. Silencing MIR22HG resulted in the loss of miR-22-3p and miR-22-5p, which upregulated the expression of their direct targets SFRP2 and PCDH15, leading to the inhibition of GBM progression. AC1L6JTK, a specific small-molecule inhibitor, efficiently suppresses tumor growth in vivo by blocking the processing of pre-miR-22 into mature miR-22. These data indicate that the interplay between miR-22 and its host gene MIR22HG might be a potential target for patients with GBM through pharmacological blockade [31] (Fig. 5a). Another independent study confirmed the important role of this interaction in cancer. In addition to its interaction with HuR, Zhang et al. also found that increased MIR22HG could markedly upregulate miR-22-3p expression levels. Additionally, MIR22HG drives miR-22-3p to target HMGB1, leading to the deactivation of HMGB1 signaling. These data demonstrate that miR-22-3p and its host gene MIR22HG are coexpressed and functionally coordinated in HCC [24] (Fig. 5b).
**Therapeutic implications of MIR22HG in cancer**

Currently, MIR22HG is included in a long list of IncRNAs that are mechanistically linked to the progression and prognosis of several types of cancer. It has been reported that MIR22HG is downregulated in GC, HCC, NSCLC, TC, CCA, and CRC and that the low expression of MIR22HG is significantly associated with poor overall survival (Table 2). Given the differential expression of MIR22HG in cancer, MIR22HG might be a novel biomarker for cancer diagnosis and prognosis. Not coincidentally, in terms of IncRNAs functioning as biomarkers, one of the most well-known examples is PCA3, a prostate-specific IncRNA previously named DD3 [87]. Considering that PCA3 is prostate tissue-specific and highly overexpressed in prostate cancer (PC) tissues compared with benign tissues, it has attracted the interest of academic researchers who validated the potential role of PCA3 as a biomarker for PC diagnosis [88–92]. Finally, in 2012, the US Food and Drug Administration (FDA) approved Progensa PCA3 as an aid for repeat biopsy decisions in men with a previous negative biopsy [93]. PCA3 is a successful example translated from an academic research laboratory into clinical practice, providing a promising future for IncRNA-based clinical applications.

Overwhelming evidence supports the proliferative and antiapoptotic roles of MIR22HG in cancer. In addition, MIR22HG exhibits extensive mechanistic diversity to carry out its functional roles; therefore, it may represent a novel target to overcome cancer. Currently, there are several clinical trials involving IncRNAs as novel biomarkers or cancer therapies (database: http://clinicaltrials.gov). Two clinical trials sponsored by Assiut University will evaluate the clinical utility of detecting the expression of the IncRNA CCAT1 in the diagnosis of CRC patients and its relation to tumor stage (NCT04269746) and investigate the IncRNAs HOTAIR and Midkine as biomarkers in TC. Furthermore, two other clinical trials are recruiting patients to validate IncRNAs as biomarkers for the detection and prognosis of lung cancer (NCT03830619) and high-grade serous ovarian cancer (HGSOC) (NCT03738319). A trial sponsored by Fudan University is currently enrolling subjects to compare the efficacy and safety between docetaxel combined with doxorubicin (epirubicin) and cyclophosphamide followed by gemcitabine combined with cisplatin and doxorubicin (epirubicin) combined with cyclophosphamide followed by docetaxel for high-risk triple-negative breast cancer predicted by the mRNA-IncRNA integrated signature and to validate the efficacy of the signature (NCT02641847). Importantly, the development of new RNA biology technologies and approaches offers more opportunities for IncRNA-targeted clinical applications. For instance, small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) are the most common RNA-targeted therapies. To efficiently and safely target RNA, some chemical modifications, such as nucleoside moieties, morpholinos, and peptidyl nucleic acids, can be introduced [94]. The biological function of MIR22HG in cancer will need to be explored in more detail, and its possible relevance to cancer therapeutic targets will also need to be examined.

Another potentially exciting use for MIR22HG may be in the area of immunotherapy. Immunotherapy is a type of cancer treatment that helps the immune system fight cancer. Checkpoint inhibitors are a type of immunotherapy that takes the brakes off the immune system and helps it recognize and attack cancer cells [95]. Although checkpoint inhibitors have made large breakthroughs in cancer treatment, remarkable responses are currently limited to a minority of patients and indications. Thus, one major concern is how we can enhance the efficiency and response rate of checkpoint inhibitors. Notably, checkpoint inhibitors do not work directly on the tumor, but their efficiency depends on whether the patient’s own T cells can infiltrate the tumor [96]. Xu and colleagues revealed that MIR22HG expression is significantly correlated with CD8A and that the overexpression of MIR22HG triggers T cell infiltration, which plays a central role in coordinating distinct types of immune responses. In this regard, MIR22HG may be a novel biomarker to predict the immunotherapy response. Further in vivo studies confirmed that mice treated with MIR22HG and PD-L1 blockade had smaller size and lower weight tumor and responded more positively to anti-PD-L1 immunotherapy than untreated mice. These findings in mice also correlate with studies of T cell infiltration as a key limiting factor for efficacious cancer immunotherapy.

**Conclusion**

Up-to-date studies have provided a comprehensive overview showing that MIR22HG is recognized as a regulator of cancer-influencing proliferation, apoptosis, and migration. MIR22HG drives the cancer phenotype through the dysregulation of oncogenic and tumor suppressive gene networks via the variety of mechanisms discussed above. Of note, its aberrant expression is closely correlated with clinicopathological parameters, such as lymphatic metastasis, tumor stage, tumor size and overall survival, providing a great opportunity as a cancer prognostic biomarker. Furthermore, with diverse modulatory mechanisms, MIR22HG has advantages that support its potential as a therapeutic target. To date, research on the mechanism of MIR22HG has made some progress but remains mainly in the preclinical stage. Future investigations will be necessary to explore the precise molecular regulatory mechanisms of MIR22HG in carcinogenesis and cancer progression to translate MIR22HG from basic research into the clinic as early as possible.
Acknowledgements

Not applicable.

Authors’ contributions

LZ and CXL contributed to literature review; XLS contributed to designing the manuscript; LZ and XLS contributed to editing and revising the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (81960560), Autonomous Region Science and Technology Achievement Transformation Fund (CGZH2018149), and Natural Science Foundation of Inner Mongolia Autonomous Region (2020BS08002).

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 29 July 2020 Accepted: 20 November 2020

Published online: 03 December 2020

References

1. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458:223–7.
2. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into function. Nat Rev Genet. 2009;10:155–9.
3. St Laurent G, Wahlstedt C, Kapanov P. The Landscape of long noncoding RNA classification. Trends Genet. 2015;31:239–51.
4. Han Z, Xue W, Tao L, Lou Y, Qiu Y, Zhu F. Genome-wide identification and analysis of the EQTL, IncRNAs in multiple sclerosis based on RNA-seq data. Brief Bioinform. 2020;21:1023–37.
5. Chen Y, Xie H, Zou Y, Lai X, Ma L, Liu Y, Li J. Tetracycline-controllable artificial microRNA–HOTAIR + EZH2 suppressed the progression of bladder cancer cells. Mol Biosyst. 2017;13:1597–607.
6. Evans JR, Feng FY, Chinnaiyan AM. The bright side of dark matter: IncRNAs in cancer. J Clin Invest. 2016;126:2755–82.
7. Weidle LH, Bizele F, Kollmorgen G, Rüger R. Long Non-coding RNAs and their Role in Metastasis. Cancer Genomics Proteomics. 2017;14:143–60.
8. Rashid F, Shah A, Shan G. Long Non-coding RNAs in the Cytoplasm. Genomics Proteomics Bioinformatics. 2016;14:73–80.
9. Kopp F, Mendell JT. Functional Classification and Experimental Dissection of Long Noncoding RNAs. Cell. 2018;172:393–407.
10. Gil N, Ulltisky I. Regulation of gene expression by cis-acting long non-coding RNAs. Nat Rev Genet. 2020;21:102–17.
11. Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D, et al. lncRNA HOXA11-AS Promotes Proliferation and Invasion of Gastric Cancer by Scaffolding the Chromatin Modification Factors PRC2, LSD1, and DNMT1. Cancer Res. 2016; 76:299–310.
12. Jiang XM, Li ZL, Li JL, Zheng WY, Li XH, Cui YF, Sun DJ. LncRNA CCAT1 as the unfavorable prognostic biomarker for cholangiocarcinoma. Eur Rev Med Pharmacol Sci. 2017;21:1242–7.
13. Li Z, Jiang X, Su Z, Li J, Kang P, Li C, Cui Y. Current insight into a cancer-impaired long non-coding RNA ZFAS1 and correlational functional mechanisms involved. Pathol Res Pract. 2018;214:1517–23.
14. Wang J, Su Z, Lu S, Fu W, Liu Z, Jiang X, Tai S. lncRNA HOXA-AS2 and its molecular mechanisms in human cancer. Clin Chim Acta. 2018;485:229–33.
15. Dai X, Kaushik AC, Zhang J. The Emerging Role of Major Regulatory RNAs in Cancer Control. Front Oncol. 2019;9:520.
16. Esposito R, Bosch N, LanzoZ A, Poldorí T, Pulido-Quetglas C, Johnson R. Hacking the Cancer Genome: Profiling Therapeutically Actionable Long Non-coding RNAs Using CRISPR-Cas9 Screening. Cancer Cell. 2019;35:45–57.
17. Li J, Jiang X, Li Z, Huang L, Zhou Y, Liu Y, Cui Y. Long noncoding RNA GHT1 in human cancer. Clin Chim Acta. 2019;498:111–5.
18. Garland W, Jensen TH. Nuclear sorting of RNA. Wiley Interdiscip Rev RNA. 2020;11:e1572.
19. Zhao X, He M, Wan D, Ye Y, He Y, Han L, et al. The minimum LOH region defined on chromosome 17p13.3 in human hepatocellular carcinoma with gene content analysis. Cancer Lett. 2003;190:221–32.
20. Zheng J, Xiong D, Sun X, Wang J, Hao M, Ding T, et al. Signification of Hypermethylated in Cancer 1 (HIC1) as Tumor Suppressor Gene in Tumor Progression. Cancer Microenviron. 2012;5:285–93.
21. Chen ZB, Cao WL, Su K, Mao M, Zeng XY, Li JH. MIR22HG inhibits cell growth, migration and invasion through regulating the miR-24-3p/PTK1β axis in thyroid papillary carcinomas. Eur Rev Med Pharmacol Sci. 2019;23:5851–62.
22. Qin L, Luo JZ, Tang XL, Han CG. Identification of Long Noncoding RNA MIR22HG as a Novel Biomarker in Thyroid Cancer. Pathol Oncol Res. 2019;25:703–10.
23. Wu Y, Zhou Y, Huan L, Xu L, Shen M, Huang S, Liang L. LncRNA MIR22HG inhibits growth, migration and invasion through regulating the miR-10a-5p/NCOA2 axis in hepatocellular carcinoma cells. Cancer Sci. 2019;110:973–84.
24. Zhang DY, Zou X, Cao CH, Zhang T, Lei L, Qi XL, et al. Identification and Functional Characterization of Long Non-coding RNA MIR22HG as a Tumor Suppressor for Hepatocellular Carcinoma. Theranostics. 2018;8:3751–65.
25. Cui Z, An X, Li J, Liu Q, Liu W. LncRNA MIR22HG negatively regulates miR-141-3p to enhance DAPK1 expression and inhibits endometrial carcinoma cells proliferation. Biomed Pharmacother. 2018;104:2223–8.
26. Hu X, Tan Z, Yang Y, Yang P. Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/β-catenin signaling pathway. J Gene Med. 2019;21:e3085.
27. Xu J, Shao T, Song M, Xie Y, Zhou J, Yin J, et al. MIR22HG acts as a tumor suppressor via TGFB/SMAD signaling and facilitates immunotherapy in colorectal cancer. Mol Cancer. 2020;19:51.
28. Li H, Wang Y. Long Noncoding RNA lncRNA MIR22HG Suppresses Gastric Cancer Progression through Attenuating NOTCH2 Signaling. Med Sci Monit. 2019;25:656–65.
29. Su W, Guo C, Wang L, Wang Z, Yang X, Niu F, et al. LncRNA MIR22HG abrogation inhibits proliferation and induces apoptosis in esophageal adenocarcinoma cells via activation of the STAT3/c-Myc/FAK signaling. Aging (Albany NY). 2019;11:4587–96.
30. Su W, Feng S, Chen X, Yang X, Mao R, Guo C, et al. Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer. Cancer Res. 2018;78:3207–19.
31. Han M, Wang S, Fritah S, Wang X, Zhou W, Yang N, et al. Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/β-catenin signalling. Brain. 2020;143:512–30.
32. Dai Q, Li J, Zhou K, Liang T. Competing endogenous RNA: A novel posttranscriptional regulatory dimension associated with the progression of cancer. Oncol Lett. 2015;10:2683–90.
33. Wang Y, Lu T, Wo Y, Sun X, Li S, Mao S, et al. Identification of a putative competitive endogenous RNA network for lung adenocarcinoma using TCGA datasets. PeerJ. 2019;7:e6819.
34. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfo MP. A ceRNA hypothesis: the Rosetta Stone of a hidden. RNA language? Cell. 2011;146:353–8.
35. Cesana M, Cacciarelli D, Legnini I, Santini T, Shandler O, Chinnapri M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011;147:358–69.
36. Tay Y, Rinn J, Pandolfo MP. The multilayered complexity of ceRNA: crossstalk competition. Nature. 2014;505:344–52.
37. Zhao G, Fu Y, Su Z, Wu R. How Long Non-Coding RNAs and MicroRNAs Mediate the Endogenous RNA Network of Head and Neck Squamous Cell Carcinoma: a Comprehensive Analysis. Cell Physiol Biochem. 2018;50:332–41.
38. Liu Y, Zhang Y, Wu H, Li Y, Zhang Y, Liu M, et al. miR-10a suppresses colorectal cancer metastasis by modulating the epithelial-to-mesenchymal transition and angiogenesis. Cell Death Dis. 2017;8:e2739.
39. Zeng T, Li G. MicroRNA10a enhances the metastatic potential of cervical cancer cells by targeting phosphatase and tensin homologue. Mol Med Rep. 2014;10:1377–82.
40. Liu S, Sun J, Lan Q. TGF-beta-induced miR10a/b expression promotes human glioma cell migration by targeting PTEN. Mol Med Rep. 2013;8: 1741–6.
41. Foley NH, Bray I, Watters KM, Das S, Bryan K, Bernas T, et al. MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ. 2011;18:1089–98.
42. Siebel C, Lendahl U. Notch Signaling in Development, Tissue Homeostasis, and Disease. Physiol Rev. 2017;97:1235–94.
43. Steinhart Z, Angers S. Wnt signaling in development and tissue homeostasis. Development. 2018; 145.
44. Vander Ark A, Cao L, Li X. TGF-beta receptors: In and beyond TGF-beta signaling. Cell Signal. 2018;52:112–20.
45. Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med. 2015; 5.
46. Perugorria MJ, Olaizola P, Labiano I, Esparza-Baquer A, Marzioni M, Marin JG, et al. Wnt-beta-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2019;16:121–36.
47. Mohammed MK, Shao C, Wang J, Wei Q, Wang X, Collier Z, et al. Wnt/beta-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis. 2016;3:11–40.
48. Lecarpentier Y, Schussler O, Hebert JL, Vallee A. Multiple Targets of the Canonical WNT/beta-Catenin Signaling Pathway. In: Vlachakis D, editor. Gene Expression Profiling in Cancer. London: IntechOpen; 2019. pp. 1–17.
49. Ma JH, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal. 2020;18:33.
50. Lesinski GB. The potential for targeting the STAT3 pathway as a novel therapy for melanoma. Future Oncol. 2013; 9:925–927.
51. Garg N, Bakhshiyani D, Venugopal C, Mahendram S, Rosa DA, Vijayakumar T, et al. CD133(+)/brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence. Oncogene. 2017;36:605–17.
52. Hajimoradi M, Mohammad Hassan Z, Ebrahim M, Soleimani M, Bakhshi M, Firouzi J, Samani FS. STAT3 is Overactivated in Gastric Cancer Stem-Like Cells. Cell J. 2016;17:617–28.
53. Koh JS, Joo MK, Park JJ, Yoo HS, Choi BI, Lee BJ, et al. Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer. Cell Biosci. 2018;850.
54. Vasquez-Dunddel D, Pan F, Zeng Q, Gorboubovn M, Albesiano E, Fu J, et al. STAT3 regulates arginase-1 in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123:5180–9.
55. Li Z, Zhao W, Wang M, Zhou X. The Role of Long Noncoding RNAs in Gene Expression Regulation. In: Vlachakis D, editor. Gene Expression Profiling in Cancer. London: IntechOpen; 2019. pp. 1–17.
56. Hu H, Zhu C, Ai H, Zhang L, Zhao J, Zhou Q, Liu H. LPI-ETSLP: IncRNA-protein interaction prediction using eigenvalue transformation-based semi-supervised link prediction. Mol Biosyst. 2017;13:1781–7.
57. Zhang W, Yue X, Tang Y, Wu W, Huang F, Zhang X. SFPFL-1: Sequence-based feature projection ensemble learning for predicting LncRNA-protein interactions. PLoS Comput Biol. 2018;14:e1006616.
58. Parveen A, Akash MS, Rehman K, Kyunnu WW. Dual Role of p21 in the Progression of Cancer and Its Treatment. Crit Rev Eukaryot Gene Expr. 2016; 26:49–62.
59. Georgakilas AG, Martin OA, Bonner WM. p21: A Two-Faced. Genome Res. 2019;29:1804–17.
60. Shamloo B, Usluer S. p21 in Cancer Research. Cancers (Basel). 2019;11.
61. Sullivan DP, Pai A, Miskovsky E, Heideman M, et al. p21 in colorectal cancer. Mol Cancer. 2017;16:129.
62. Nowell CS, Radtke F. Notch as a tumour suppressor. Blood. 2014;123:2451–9.
63. Mariathasan S, Turley SJ, Nickels D, Castiglioni A, Yuen K, Wang Y, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–8.
64. Bray SJ. Notch signalling in context. Nat Rev Mol Cell Biol. 2016;17:722–35.
65. Kovetyopoulou Z, Panahi F, Vakilian M, Feymann M, Seyed Forootan F, Nasr Esfahani MH, Ghadik L. Signaling pathways involved in colorectal cancer progression. Cell Biosci. 2019:97.
66. Lobey C, Oh P, Mansour MR, Look AT, Afantis I. Notch signaling: switching an oncogene to a tumor suppressor. Blood. 2014;123:2451–9.
67. Tsai M, Marberger M, Horvath S, Czyppre C. D3DPC3A RNA analysis in urine—a new perspective for detecting prostate cancer. Eur Urol. 2004;46:182–6.
68. discussion 187.
90. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52:1089–95.

91. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1987–92.

92. van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, et al. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int. 2012;109:360–6.

93. Loeb S. Prostate cancer: Predicting prostate biopsy results—PCA3 versus phi. Nat Rev Urol. 2015;12:130–1.

94. Crooke ST, Witzum JL, Bennett CF, Baker BF. RNA-Targeted Therapeutics. Cell Metab. 2018;27:714–39.

95. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8:1069–86.

96. Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014;4:522–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.